Gamma knife radiosurgery for uveal melanoma ineligible for brachytherapy by the Collaborative Ocular Melanoma Study criteria
Nicola G Ghazi1, Christopher S Ketcherside1, Jason Sheehan2, Brian P Conway1
1Department of Ophthalmology and 2Neurosurgery, University of Virginia Health System, Charlottesville, VA, USA
Purpose: To report outcomes of Gamma Knife radiosurgery (GKRS) in treating uveal melanoma lesions ineligible for standard brachytherapy.
Methods: A retrospective interventional case series of uveal melanoma patients treated with GKRS between 1996 and 2004 was performed. The main outcome measures were local tumor control, metastasis, and death.
Results: Four patients with uveal melanoma treated with GKS were identified. Three tumors involved the ciliary body and one was macular with its border within 2 mm of the optic disc. Adequate globe stabilization was achieved by retrobulbar anesthesia in all cases. Pretreatment mean visual acuity was 20/30. Tumor volume as determined by magnetic resonance imaging ranged from 0.05 to 0.30 cc. Ultrasonographic greatest tumor diameter and height ranged from 11 to 18 mm (mean 14.5 mm) and 2.9 to 4.5 mm (mean 3.6 mm), respectively. The peripheral dose varied from 16.5 to 30 Gray. Local tumor control was achieved in all cases over a follow up period of 6 to 96 months. Mean final visual acuity was 20/50. One eye was enucleated for neovascular glaucoma and one patient died from liver and lung metastasis.
Conclusions: GKRS for uveal melanoma appears to be safe and effective. The metastasis and mortality rates appear to be comparable to those following brachytherapy and enucleation. Moreover, local tumor control and enucleation rates are similar to those following brachytherapy. The findings in this small series suggest a role for GKRS in the treatment of selected cases of uveal melanomas.
Keywords: gamma knife radiosurgery, radiation therapy, uveal melanoma
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF]
Other article by this author:
Is reduction in the risk of vision loss the only benefit of photodynamic therapy in predominantly classic subfoveal choroidal neovascularization?
Nicola G Ghazi, Brian P Conway, James S Tiedeman, Steven J Yoon
Published Date: 5 December 2008
Readers of this article also read:
Hopp CD, Land MF
Published Date: 18 April 2013
Jantus-Lewintre E, Usó M, Sanmartín E, Camps C
Published Date: 12 June 2012
Published Date: 29 May 2012
Published Date: 19 May 2011
Brianne L Dunn, Walter E Uber, John S Ikonomidis
Published Date: 23 October 2009
Mo Al-Qaisi, David M Nott, David H King, et al
Published Date: 30 September 2009
Selecting the optimal antithrombotic regimen for patients with acute coronary syndromes undergoing percutaneous coronary intervention
Shailja V Parikh, Ellen C Keeley
Published Date: 19 August 2009
Giuseppe Micieli, Simona Marcheselli, Piera Angela Tosi
Published Date: 8 May 2009
Cecile Tissot, Maurice Beghetti
Published Date: 8 April 2009
Rajan Sharma, Denis Pellerin
Published Date: 24 November 2008